210 related articles for article (PubMed ID: 30024511)
21. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
Bang YH; Ryu MH; Kim HD; Lee HE; Kang YK
Int J Cancer; 2022 Nov; 151(10):1770-1777. PubMed ID: 35678337
[TBL] [Abstract][Full Text] [Related]
23. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
24. Primary Gastrointestinal Stromal Tumor Mimicking as Gynecologic Mass: Characteristics, Management, and Prognosis.
Tao K; Zeng X; Liu W; Wang S; Gao J; Shuai X; Zhang P
J Surg Res; 2020 Feb; 246():584-590. PubMed ID: 31653414
[TBL] [Abstract][Full Text] [Related]
25. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
[TBL] [Abstract][Full Text] [Related]
26. Assessing prognostic factors of long-term survival after surgery for colorectal gastrointestinal stromal tumours.
Yang S; Maspero M; Holubar SD; Hull TL; Lightner AL; Valente MA; Gorgun E; Kalady MF; Steele SR; Liska D
Colorectal Dis; 2023 Dec; 25(12):2325-2334. PubMed ID: 37876119
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.
Kang S; Ryu MH; Bang YH; Kim HD; Lee HE; Kang YK
Cancer Res Treat; 2022 Oct; 54(4):1167-1174. PubMed ID: 34883555
[TBL] [Abstract][Full Text] [Related]
28. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.
Shi YN; Li Y; Wang LP; Wang ZH; Liang XB; Liang H; Zhang L; Li B; Fan LQ; Zhao Q; Ma ZX; Zhao XF; Zhang ZD; Liu Y; Tan BB; Wang D; Wang LL; Hao YJ; Jia N
Medicine (Baltimore); 2017 Nov; 96(46):e8240. PubMed ID: 29145240
[TBL] [Abstract][Full Text] [Related]
31. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Rubió-Casadevall J; Martinez-Trufero J; Garcia-Albeniz X; Calabuig S; Lopez-Pousa A; Del Muro JG; Fra J; Redondo A; Lainez N; Poveda A; Valverde C; De Juan A; Sevilla I; Casado A; Andres R; Cruz J; Martin-Broto J; Maurel J;
Ann Surg Oncol; 2015 Sep; 22(9):2948-57. PubMed ID: 25608769
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
33. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
Tang S; Yin Y; Shen C; Chen J; Yin X; Zhang B; Yao Y; Yang J; Chen Z
World J Surg Oncol; 2017 Apr; 15(1):79. PubMed ID: 28399894
[TBL] [Abstract][Full Text] [Related]
34. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Eriksson M; Reichardt P; Sundby Hall K; Schütte J; Cameron S; Hohenberger P; Bauer S; Leinonen M; Reichardt A; Rejmyr Davis M; Alvegård T; Joensuu H
Eur J Cancer; 2016 May; 59():128-133. PubMed ID: 27033260
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report.
Blay JY; Levard A
Anticancer Drugs; 2016 Jan; 27(1):71-5. PubMed ID: 26457546
[TBL] [Abstract][Full Text] [Related]
36. Treatment Access for Gastrointestinal Stromal Tumor in Predominantly Low- and Middle-Income Countries.
Briercheck EL; Wrigglesworth JM; Garcia-Gonzalez I; Scheepers C; Ong MC; Venkatesh V; Stevenson P; Annamalay AA; Coffey DG; Anderson AB; Garcia-Gonzalez P; Wagner MJ
JAMA Netw Open; 2024 Apr; 7(4):e244898. PubMed ID: 38568688
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
[TBL] [Abstract][Full Text] [Related]
38. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG
JAMA Surg; 2020 Jun; 155(6):e200397. PubMed ID: 32236507
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.
Ogata K; Kimura A; Nakazawa N; Suzuki M; Yanoma T; Ubukata Y; Iwamatsu K; Kogure N; Yanai M; Kuwano H
Digestion; 2018; 97(1):20-25. PubMed ID: 29393163
[TBL] [Abstract][Full Text] [Related]
40. Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis.
Bischof DA; Dodson R; Jimenez MC; Behman R; Cocieru A; Blazer DG; Fisher SB; Squires MH; Kooby DA; Maithel SK; Groeschl RT; Gamblin TC; Bauer TW; Karanicolas PJ; Law C; Quereshy FA; Pawlik TM
J Gastrointest Surg; 2015 Jun; 19(6):1022-8. PubMed ID: 25731828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
